Systemic Combination Virotherapy for Melanoma with Tumor Antigen-Expressing Vesicular Stomatitis Virus and Adoptive T-cell Transfer
Authors:
- 15 September 2012
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 72 (18) , 4753-4764
Abstract
Oncolytic virotherapy offers the potential to treat tumors both as a single agent and in combination with traditional modalities such as chemotherapy and radiotherapy. Here we describe an effective, fully systemic treatment regimen, which combines virotherapy, acting essentially as an adjuvant immunotherapy, with adoptive cell transfer (ACT). The combination of ACT with systemic administration of a vesicular stomatitis virus (VSV) engineered to express the endogenous melanocyte antigen glycoprotein 100 (gp100) resulted in regression of established melanomas and generation of antitumor immunity. Tumor response was associated with in vivo T-cell persistence and activation as well as treatment-related vitiligo. However, in a proportion of treated mice, initial tumor regressions were followed by recurrences. Therapy was further enhanced by targeting an additional tumor antigen with the VSV-antigen + ACT combination strategy, leading to sustained response in 100% of mice. Together, our findings suggest that systemic virotherapy combined with antigen-expressing VSV could be used to support and enhance clinical immunotherapy protocols with adoptive T-cell transfer, which are already used in the clinic. Cancer Res; 72(18); 4753–64. ©2012 AACR.Keywords
All Related Versions
This publication has 40 references indexed in Scilit:
- Interfering With Tumor Pathways That Augment Viral OncolysisMolecular Therapy, 2011
- Activating Systemic T-Cell Immunity Against Self Tumor Antigens to Support Oncolytic Virotherapy with Vesicular Stomatitis VirusHuman Gene Therapy, 2011
- VSV Oncolytic Virotherapy in the B16 Model Depends Upon Intact MyD88 SignalingMolecular Therapy, 2011
- Intelligent Design: Combination Therapy With Oncolytic VirusesMolecular Therapy, 2010
- The Case of Oncolytic Viruses Versus the Immune System: Waiting on the Judgment of SolomonHuman Gene Therapy, 2009
- Cell Carriers for Oncolytic Viruses: Fed Ex for Cancer TherapyMolecular Therapy, 2009
- Recombinant Vesicular Stomatitis Virus Transduction of Dendritic Cells Enhances Their Ability to Prime Innate and Adaptive Antitumor ImmunityMolecular Therapy, 2009
- Pharmacologic and Chemical Adjuvants in Tumor VirotherapyChemical Reviews, 2009
- Adoptive cell therapy for the treatment of patients with metastatic melanomaCurrent Opinion in Immunology, 2009
- Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumorsGene Therapy, 2008